This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: Eurofins’ Cellmark buyout saved by ‘exiting firm’ defense despite UK market heft

By Natalie McNelis ( August 20, 2024, 15:11 GMT | Comment) -- Eurofins Scientific's takeover of Cellmark, its main DNA testing and forensic services competitor in the UK, has won a speedy nod from the country’s merger watchdog despite resulting in eye-watering combined market shares — in the order of 80 to 90 percent. That's because the CMA was convinced that the situation would have been the same or worse if it blocked the deal, and it had to act quickly to avoid Cellmark’s insolvency.Eurofins Scientific's takeover of Cellmark, its main DNA testing and forensic services competitor in the UK, has won a speedy nod from the country’s merger watchdog despite resulting in eye-watering combined market shares — in the order of 80 to 90 percent. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login